Procainamide adverse reactions: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Procainamide}} {{CMG}}; {{AE}} {{SS}} ==Adverse Reactions== '''Cardiovascular System''': Hypotension nd serious disturbances of cardiorhythm such as ventric...")
 
(Redirected page to Procainamide#Adverse Reactions)
 
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Procainamide#Adverse Reactions]]
{{Procainamide}}
{{CMG}}; {{AE}} {{SS}}
 
==Adverse Reactions==
 
'''Cardiovascular System''': [[Hypotension]]  nd serious disturbances of cardiorhythm such as ventricular asystole or fibrillation are more common with intravenous administration of PA than with intramuscular administration. Because PA is a peripheral vasodilator in concentrations higher than the usual therapeutic range, transient high plasma levels which may occur especially during intravenous administration may produce temporary but at times severe lowering of blood pressure (see OVERDOSAGE andPRECAUTIONS).
 
'''Multisystem''': A [[lupus erythematosus]]-like syndrome of [[arthralgia]], pleural or abdominal pain, and sometimes [[arthritis]], [[pleural effusion]], [[pericarditis]], [[fever]], [[chills]], [[myalgia]], and possibly related hematologic or skin lesions (see below) is fairly common after prolonged PA administration, perhaps more often in patients who are slow [[acetylators]] (See Boxed Warning and PRECAUTIONS). While some series have reported less than 1 in 500, others have reported the syndrome in up to 30 percent of patients on long term oral PA therapy. If discontinuation of PA does not reverse the [[lupoid symptoms]], corticosteroid treatment may be effective.
 
'''Hematologic''': [[Neutropenia]], [[thrombocytopenia]], or [[hemolytic anemia]] may rarely be encountered. [[Agranulocytosis]] has occurred after repeated use of PA, and deaths have been reported. (See Boxed Warning, WARNINGS section.)
 
'''Skin''': [[Angioneurotic edema]], [[urticaria]], [[pruritus]], [[flushing]], and [[maculopapular rash]] have also occurred.
 
'''Gastrointestinal System''': [[Anorexia]], [[nausea]], [[vomiting]], abdominal pain, [[diarrhea]] or bitter taste may occur in 3 to 4 percent of patients taking oral procainamide.
 
'''Nervous System''': [[Dizziness]] or giddiness, weakness, mental [[depression]] and [[psychosis]] with [[hallucinations]] have been reported.
 
'''Elevated Liver Enzymes''': Elevations of transaminase with and without elevations of alkaline phosphatase and [[bilirubin]] have been reported. Some patients have had clinical symptoms (e.g., [[malaise]], right upper quadrant pain). Deaths from liver failure have been reported.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = PROCAINAMIDE HYDROCHLORIDE INJECTION, SOLUTION [HOSPIRA, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=17e47845-daad-434c-a784-6d3875b0d704 | publisher =  | date =  | accessdate = 11 March 2014 }}</ref>
==References==
{{Reflist}}
 
[[Category:Benzamides]]
[[Category:Anilines]]
[[Category:Sodium channel blockers]]
[[Category:Antiarrhythmic agents]]
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]

Latest revision as of 21:57, 21 July 2014